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PIN5
A META-ANALYSIS OF THREE-DAY AZITHROMYCIN THERAPY
VERSUS LONGER COURSES OF COMPARATOR ANTIBIOTICS
IN ACUTE SINUSITIS
Harnett J, Enuha S, Xuan J, Cappelleri J
Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: The objective of this meta-analysis is to review
published clinical trials evaluating the relative efﬁcacy of a three-
day regimen of azithromycin versus longer courses of compara-
tor antibiotics. METHODS: A literature search using Medline
and Embase identiﬁed randomized controlled trials that were
published in the English language and evaluated the efﬁcacy of
a 3-day regimen of azithromycin versus 10 days of active com-
parators in adult patients with acute sinusitis. Pooled odds ratios
were calculated for clinical success (cure + improvement) at the
end of therapy (range: day 10–15) using the Mantel-Haenszel
ﬁxed-effect and random-effect models. RESULTS: Among the 7
eligible studies with 1721 patients, the estimated overall success
rate at the end of therapy (random effect odds ratio: 1.13, 95%
CI: 0.79–1.62) was in favor of azithromycin, although this dif-
ference did not reach statistical signiﬁcance. There were no dif-
ferences in ﬁndings between the ﬁxed- and random-effect
models. CONCLUSIONS: A 3-day regimen of azithromycin has
at least comparable efﬁcacy to longer courses of comparator
antibiotics.
PIN6
TAMPON-RELATED TOXIC SHOCK SYNDROME (TSS)
CONTINUES TO PEAK AMONG ADOLESCENT GIRLS: A
NATIONWIDE HOSPITAL STUDY
Bright R, Cope J
Food and Drug Administration, Rockville, MD, USA
Despite the removal of certain types of tampons from the market,
tampon-related TSS may still lead to lengthy hospitalization and
morbidity for adolescent girls. TSS may be confused with other
acute illnesses. OBJECTIVE: To investigate the national rates of
TSS hospitalizations among adolescent girls. METHODS: Data
from the Health care Cost and Utilization Project (HCUP), col-
lected by the US Agency for Health care Research and Quality,
were used for these analyses. The HCUP Nationwide Inpatient
Sample (NIS), years 1996–2001, was obtained for ages 10–19,
20–39, and 40–59. Tampon-related TSS was computed as the
age-speciﬁc rate in females minus the age-speciﬁc rate in males.
Weighted national estimates for each sex-speciﬁc age group were
calculated by month of the year and by year. The HCUP Kids’
Inpatient Database (KID), 1997, was divided into ages 0–4, 5–9,
10–14, and 15–18 years. Sex-speciﬁc age group compared
Numbers of TSS cases. RESULTS: The highest national annual
number of tampon-related TSS hospitalizations was for 10–19
year olds, averaging 197 during the years 1996–2001. By con-
trast, the national average annual number of TSS hospitalization
for boys age 10–19 was 76, of tampon-related TSS hospitaliza-
tions for 20–39 year old women was 278, and of tampon-related
TSS hospitalizations for 40–59 year old women was 94. TSS
death rates were lowest for teens. Teen girls demonstrated a
unique pattern of elevated rates during the school months. The
KID data showed that TSS peaked for girls age 15–18, who suf-
fered nearly half of all cases among girls. Below age 10 similar
numbers of TSS occurred for boys and girls. CONCLUSION:
Increased awareness of TSS and related conditions should be
further deﬁned for subpopulations of adolescent girls who may
be at higher risk.
PIN7
CHANGES IN HIV ANTIVIRAL PHENOTYPIC DRUG
RESISTANCE DURING THE HAART ERA
Hess GP, Nelson C, Seiders J
Surveillance Data, Plymouth Meeting, PA, USA
OBJECTIVE: Patients newly diagnosed with HIV infection are
treated initially with three-drug regimens, and many patients
have been treated with drugs from three different classes of
inhibitors. Optimization of treatment strategies has resulted in
improved survival, but resistance develops readily in many
patients, and correlates with availability of and exposure to anti-
retroviral therapy. We studied patient-level trends and variation
in phenotypic resistance at several times during the HAART era
in the four major U.S. census regions. METHODS: An auto-
mated percent sample of patient-level phenotypic resistance
testing data from Virologic Inc. was analyzed for July
20101–June 2003. Test results were assigned to zip codes, unique
synthetic markers were generated for each record, and protected
health information was deleted. 1) Data at the national level was
analyzed comparing the average rate of phenotypic resistance
seen for each antiviral class in July 2001–June 2002 compared
to July 2002–June 2003, and 2) for each US census region com-
pared to the US-wide average. Results were analyzed for statis-
tically signiﬁcant differences. RESULTS: There were 500,000 +
phenotypic drug resistance tests results in the combined study
period. 1) No signiﬁcant differences were seen in the average US-
wide phenotypic resistance by class for July 2002–June 2003
compared to July 2001–June 2002. 2) Signiﬁcant differences
were seen for patient level phenotypic resistance by class when
comparing various Regions to the US-wide average, and when
comparing regions to each other. CONCLUSION: While the
average phenotypic resistance to HIV antivirals by class
remained unchanged from the 12-month comparative periods,
signiﬁcant differences exist across Regions. Clinicians need to
consider Regional variation in susceptibility to HIV antivirals in
interpreting national ﬁndings and guidelines, and in patient-level
prescribing decisions.
PIN8
AN EVIDENCE BASED PROPOSAL TO MODIFY PRESCRIBING
PATTERNS: THE CASE OF METRONIDAZOL USED WHEN
INTESTINAL AMOEBIASIS IS SUSPECTED
Medecigo-Micete C, Garduno-Espinosa J, Constantino-Casas P,
Gomez-Delgado A, Munoz-Hernandez O
Mexican Institute for Social Security, Mexico City, Mexico
OBJECTIVES: To discuss the importance of published evidence
to modify prescribing behaviours and to describe the case of
metronidazol in suspected intestinal amoebiasis. METHODS: In
Mexico and developing countries intestinal, amoebiasis is over
diagnosed in acute diarrhoea (Entamoeba histolytica found only
in 2%) with the consequent over use of metronidazol (40–60%).
We reviewed 90,700 prescriptions during August 1999 in three
primary care facilities in Mexico City. A total of 1790 prescrip-
tions of oral metronidazol were found and 300 were randomly
chosen to review the medical charts (diagnosis and dosage char-
acteristics). Micro-costing was also performed using the prices
of the institution. RESULTS: Metronidazol was prescribed when
intestinal amoebiasis was suspected in 746 cases (83%). The pre-
scriptions did not follow the established criteria (WHO and
other authors) in 96% (n = 724). Metronidazol was prescribed
when there was diarrhoea with mucus and blood in 57% and in
unspeciﬁed data of “colitis” in 39%. Only in 8 cases asympto-
matic amoebiasis was diagnosed. Mean monthly cost per medical
ofﬁce of unjustiﬁed metronidazol prescription was $43.5
Mexican pesos (4 USD). The national annual projection of that
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institution was $3,495,887 (322,350 USD). Sensitivity analysis
for the worst scenario (3% of metronidazol prescriptions, 96%
unjustiﬁed prescriptions and a higher unit price) would lead to
an annual cost of $5,193,064 (478,844 USD). CONCLUSIONS:
Inadequate prescribing criteria persists for metronidazol despite
of clinical criteria and published evidences. Our study showed
that there is a gap between medical practice and clinical and
health economics research. There is also an opportunity to
update clinicians’ knowledge using educational strategies.
Another challenge is to educate patients in the sense that drugs
prescription is not always the best option but hygiene, good 
sanitary conditions and nutrition, and prevention. Finally the
opportunity cost of unjustiﬁed prescriptions should not be
underestimated but more often evaluated and taken into account
for policies.
PIN9
VARIABILITY IN THE USE OF HIV PHENOTYPIC TESTING BY
SPECIALTY OF PRACTITIONER
Hess GP, Nelson C, Lipskiy N
Surveillance Data, Plymouth Meeting, PA, USA
OBJECTIVE: HIV treatment has involved infectious disease 
specialists and other specialties. We studied the relative use of
phenotypic resistance testing among specialties and by different
regions in the U.S over time. METHODS: Phenotypic resistance
testing data from Virologic was aggregated for 7/01 ¨C 6/03.
Tests were assigned to each ordering physicians. Self-reported
specialty was identiﬁed and an automated sample generated. Spe-
cialties were grouped as infectious disease, internal medicine,
primary care (family practice & general practice) and all others.
“Unspeciﬁed” physician records were deleted. Data were ana-
lyzed for statistically signiﬁcant differences in: the average use of
resistance testing by each specialty in July 2001–June 2002 com-
pared to July 2002–June 2003 across the US, and the use of resis-
tance testing in the each US census region compared to the
average US-wide use for each respective specialty. RESULTS:
There were approximately 2600 physicians in the sample for
which 250,000 drug resistance tests were conducted. It showed
across the US the average use of phenotypic resistance testing by
Infectious Disease statistically increased 5% (p ≥ 0.05) for July
2002–June 2003 compared to July 2001–June 2002 and the use
by other specialties decreased. Within each specialty there were
statistically signiﬁcant differences by geographic region in the use
of phenotypic resistance testing. CONCLUSION: Based on its
relative ease of interpretation compared to genotypic informa-
tion we might have predicted that the use of phenotypic 
resistance testing would increase for non-Infectious Disease spe-
cialists. The reverse was true i.e. it increased for Infectious
Disease relative to other specialties use. Signiﬁcant differences in
the use of phenotypic resistance testing were also seen by regions.
Contributing factors may include increasing adoption of pheno-
typic resistance testing by Infectious Disease specialists, variation
in patient severity and ﬁnancial constraints.
PIN10
OFF-LABEL USE OF PIPERACILLIN/TAZOBACTAM (ZOSYN®)
IN A PEDIATRIC UNIT
Thaker DJ1,Wilson JP2, Browne BA1, Godley PJ1
1Scott & White Health Plan,Temple,TX, USA; 2University of Texas,
Austin,TX, USA
OBJECTIVE: The intravenous piperacillin/tazobactam antibiotic
combination product does not currently carry an indication for
pediatric use in the United States. Despite the lack of established
pediatric safety data in the US, piperacillin/tazobactam is com-
monly prescribed for the treatment of infectious diseases in this
population. This study examines the safety of intravenous (IV)
piperacillin/tazobactam prescribed off-label to hospitalized pedi-
atric patients. METHODS: This protocol is an on-going (>2
years duration) observational study evaluating off-label medica-
tion usage in the pediatric population. The pharmacy order entry
system, containing all medications prescribed to a patient during
hospitalization, is examined on a twice-weekly basis to identify
patients admitted to a general pediatric unit who receive off-label
IV piperacillin/tazobactam. Charts of identiﬁed patients are then
reviewed to determine applicable medical history and outcomes
of piperacillin/tazobactam use. RESULTS: Forty-three courses of
IV piperacillin/tazobactam were administered to 39 pediatric
patients ranging in age from 5 months to 18 years (mean + SD
9.7 + 5.7 years). The mean weight of the patients was 29.2kg
(range 6.5 to 70.3g). The average dose and duration of
piperacillin/tazobactam therapy was 9.6g/day (range 1.8 to 18
g) and 6.4 days (1 to 20 days), respectively. Of the 43 pediatric
observations, no adverse drug events were reported resulting
from piperacillin/tazobactam administration. CONCLUSIONS:
Availability of combination antibiotic medications approved for
use in hospitalized pediatric patients is limited. Based on the
small number of patients in this review, off-label use of
piperacillin/tazobactam appears to be a safe selection in the 
management of infectious disease in a general hospital pediatric
unit. However, further investigation involving larger pediatric
populations is required to establish the true safety of
piperacillin/tazobactam in hospitalized pediatric patients.
PIN11
TESTING AND TREATMENT OF HEPATITIS C IN THE
LOUISIANA MEDICAID POPULATION
Blake SG, Dalal A, Leader WG
The University of Louisiana at Monroe School of Pharmacy, Monroe,
LA, USA
OBJECTIVES: Chronic hepatitis C is a major public health
problem whose incidence is expected to increase. But, treatments
are available that can eliminate the virus in about 50% of cases.
The purposes of this research were to: examine the prevalence
in the Louisiana Medicaid population, determine testing rates
and follow-up physician visits in at-risk populations and
examine treatment of hepatitis C. METHODS: The was a ret-
rospective analysis of Louisiana Medicaid medical and pharmacy
claims. RESULTS: The 3-year prevalence of hepatitis C as deter-
mined by a primary or secondary diagnosis was 7.08 per 1000.
Of those diagnosed from 1998–2000, 35% were age 41–50;
31%, age 21–40; and 23%, age 51–64. Of the 25,788 recipients
who were tested for hepatitis C in the 3-year period, the highest
testing rate in at-risk groups was among those with hepatitis B
with almost 73% having had a hepatitis C test. Other at-risk
groups were not tested at that rate. Of the 25,788 tested for
hepatitis C, 17,385 received follow-up care (an outpatient 
physician visit within 90 days of the test). Of those who were
tested, 643 received a diagnosis of hepatitis C with 489 (76%)
receiving treatment. Of those treated, 364 (74.44%) started on
monotherapy and 125 (25.56%) started on combination therapy.
Switches from monotherapy to combination therapy were
common. After 6 months, 132 had switched to combination
therapy and 204 had switched by 12 months. Of those diagnosed
with cirrhosis, 88.07% also had a diagnosis of hepatitis C. Of
recipients with other advanced liver disease, 53.47% had a
hepatitis C diagnosis. CONCLUSIONS: There is a high preva-
lence of hepatitis C in the Louisiana Medicaid program. Many
at risk-recipients are not being tested. Of those tested, most
received follow up care and most diagnosed with hepatitis C
were receiving treatment.
